A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT04856930. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
Study identification
- NCT ID
- NCT04856930
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 6, 2021
- Primary completion
- Jul 14, 2022
- Completion
- Dec 13, 2022
- Last update posted
- Sep 21, 2025
2021 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 10-108 | Birmingham | Alabama | 35224 | — |
| Site 10-104 | Fountain Valley | California | 92708 | — |
| Site 10-119 | Northridge | California | 91324 | — |
| Site 10-102 | Sacramento | California | 95817 | — |
| Site 10-109 | Coral Gables | Florida | 33134 | — |
| Site 10-107 | Largo | Florida | 33770 | — |
| Site 10-111 | Tampa | Florida | 33607 | — |
| Site 10-110 | Sandy Springs | Georgia | 30328 | — |
| Site 10-101 | Fort Gratiot | Michigan | 48059 | — |
| Site 10-103 | Portsmouth | New Hampshire | 03801 | — |
| Site 10-115 | Warwick | Rhode Island | 02886 | — |
| Site 10-113 | Greenville | South Carolina | 29615 | — |
| Site 10-118 | Houston | Texas | 77056 | — |
| Site 10-112 | Pflugerville | Texas | 78660 | — |
| Site 10-117 | San Antonio | Texas | 78213 | — |
| Site 10-105 | Norfolk | Virginia | 23502 | — |
| Site 10-106 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04856930, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04856930 live on ClinicalTrials.gov.